Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study.

Tsai JN, Burnett-Bowie SM, Lee H, Leder BZ

Bone11 Nov 2016Cited by 23 (Europe PMC)

PMID27840301PMCIDPMC6941193DOI10.1016/j.bone.2016.11.009PepBankPUB-27840301

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In women receiving teriparatide, baseline bone turnover markers did not correlate with BMD changes over 2 years.
In plain wordsIn women receiving teriparatide, starting bone turnover markers were not linked to later bone density changes.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableBaseline turnover markers and BMD
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In women receiving teriparatide, baseline BTMs did not correlate with 2-year BMD changes though 12-month increases in osteocalcin and P1NP were associated with 2-year increases in spine BMD.
2 context sentences(design, population, supporting numbers)
Summary · context
In the DATA study, 94 postmenopausal osteoporotic women (ages 51-91) received either teriparatide 20-mcg SC daily, denosumab 60-mg SC every 6months, or both for 2years.
Summary · context
Pearson's correlation coefficients (R) were calculated to determine the relationship between baseline and early changes in BTMs (as well as serum sclerostin) and 2-year changes in BMD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2784030101
02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In women receiving teriparatide, osteocalcin increases at 12 months were associated with spine BMD increases at 2 years.
In plain wordsIn women receiving teriparatide, increased osteocalcin was linked to later spine bone density gains.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableOsteocalcin change and spine BMD
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In women receiving teriparatide, baseline BTMs did not correlate with 2-year BMD changes though 12-month increases in osteocalcin and P1NP were associated with 2-year increases in spine BMD.
2 context sentences(design, population, supporting numbers)
Summary · context
In the DATA study, 94 postmenopausal osteoporotic women (ages 51-91) received either teriparatide 20-mcg SC daily, denosumab 60-mg SC every 6months, or both for 2years.
Summary · context
Pearson's correlation coefficients (R) were calculated to determine the relationship between baseline and early changes in BTMs (as well as serum sclerostin) and 2-year changes in BMD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2784030102
03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In women receiving teriparatide, P1NP increases at 12 months were associated with spine BMD increases at 2 years.
In plain wordsIn women receiving teriparatide, increased P1NP was linked to later spine bone density gains.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableP1NP change and spine BMD
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In women receiving teriparatide, baseline BTMs did not correlate with 2-year BMD changes though 12-month increases in osteocalcin and P1NP were associated with 2-year increases in spine BMD.
2 context sentences(design, population, supporting numbers)
Summary · context
In the DATA study, 94 postmenopausal osteoporotic women (ages 51-91) received either teriparatide 20-mcg SC daily, denosumab 60-mg SC every 6months, or both for 2years.
Summary · context
Pearson's correlation coefficients (R) were calculated to determine the relationship between baseline and early changes in BTMs (as well as serum sclerostin) and 2-year changes in BMD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2784030103
04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In women receiving teriparatide plus denosumab, baseline P1NP was associated with spine BMD gains.
In plain wordsIn women receiving teriparatide plus denosumab, starting P1NP was linked to spine bone density gains.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableBaseline P1NP and spine BMD with combination
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In women receiving combined teriparatide/denosumab, while both baseline and decreases in P1NP were associated with spine BMD gains, distal radius increases were associated with less CTX suppression.
2 context sentences(design, population, supporting numbers)
Summary · context
In the DATA study, 94 postmenopausal osteoporotic women (ages 51-91) received either teriparatide 20-mcg SC daily, denosumab 60-mg SC every 6months, or both for 2years.
Summary · context
Pearson's correlation coefficients (R) were calculated to determine the relationship between baseline and early changes in BTMs (as well as serum sclerostin) and 2-year changes in BMD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2784030104
05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In women receiving teriparatide plus denosumab, P1NP decreases were associated with spine BMD gains.
In plain wordsIn women receiving teriparatide plus denosumab, decreased P1NP was linked to spine bone density gains.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableP1NP decrease and spine BMD with combination
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In women receiving combined teriparatide/denosumab, while both baseline and decreases in P1NP were associated with spine BMD gains, distal radius increases were associated with less CTX suppression.
2 context sentences(design, population, supporting numbers)
Summary · context
In the DATA study, 94 postmenopausal osteoporotic women (ages 51-91) received either teriparatide 20-mcg SC daily, denosumab 60-mg SC every 6months, or both for 2years.
Summary · context
Pearson's correlation coefficients (R) were calculated to determine the relationship between baseline and early changes in BTMs (as well as serum sclerostin) and 2-year changes in BMD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2784030105
06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In women receiving teriparatide plus denosumab, distal radius BMD increases were associated with less CTX suppression.
In plain wordsIn women receiving teriparatide plus denosumab, forearm bone density gains were linked to less CTX suppression.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableCTX suppression and distal radius BMD with combination
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In women receiving combined teriparatide/denosumab, while both baseline and decreases in P1NP were associated with spine BMD gains, distal radius increases were associated with less CTX suppression.
2 context sentences(design, population, supporting numbers)
Summary · context
In the DATA study, 94 postmenopausal osteoporotic women (ages 51-91) received either teriparatide 20-mcg SC daily, denosumab 60-mg SC every 6months, or both for 2years.
Summary · context
Pearson's correlation coefficients (R) were calculated to determine the relationship between baseline and early changes in BTMs (as well as serum sclerostin) and 2-year changes in BMD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2784030106
07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In women receiving teriparatide, neither baseline nor changes in serum sclerostin correlated with BMD.
In plain wordsIn women receiving teriparatide, starting sclerostin and its changes were not linked to bone density.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSclerostin and BMD with teriparatide
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Neither baseline nor changes in serum sclerostin correlated with BMD in any treatment group.
2 context sentences(design, population, supporting numbers)
Summary · context
In the DATA study, 94 postmenopausal osteoporotic women (ages 51-91) received either teriparatide 20-mcg SC daily, denosumab 60-mg SC every 6months, or both for 2years.
Summary · context
Pearson's correlation coefficients (R) were calculated to determine the relationship between baseline and early changes in BTMs (as well as serum sclerostin) and 2-year changes in BMD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2784030107
08HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In women receiving teriparatide plus denosumab, neither baseline nor changes in serum sclerostin correlated with BMD.
In plain wordsIn women receiving teriparatide plus denosumab, starting sclerostin and its changes were not linked to bone density.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSclerostin and BMD with combination
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Neither baseline nor changes in serum sclerostin correlated with BMD in any treatment group.
2 context sentences(design, population, supporting numbers)
Summary · context
In the DATA study, 94 postmenopausal osteoporotic women (ages 51-91) received either teriparatide 20-mcg SC daily, denosumab 60-mg SC every 6months, or both for 2years.
Summary · context
Pearson's correlation coefficients (R) were calculated to determine the relationship between baseline and early changes in BTMs (as well as serum sclerostin) and 2-year changes in BMD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2784030108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.